JP2019505493A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019505493A5 JP2019505493A5 JP2018531186A JP2018531186A JP2019505493A5 JP 2019505493 A5 JP2019505493 A5 JP 2019505493A5 JP 2018531186 A JP2018531186 A JP 2018531186A JP 2018531186 A JP2018531186 A JP 2018531186A JP 2019505493 A5 JP2019505493 A5 JP 2019505493A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- peg
- trough concentration
- serum trough
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims description 74
- 108090000174 Interleukin-10 Proteins 0.000 claims description 28
- 102000003814 Interleukin-10 Human genes 0.000 claims description 28
- 210000002966 serum Anatomy 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 101001033233 Homo sapiens Interleukin-10 Proteins 0.000 claims description 6
- 102000052620 human IL10 Human genes 0.000 claims description 6
- 230000001988 toxicity Effects 0.000 claims description 6
- 231100000419 toxicity Toxicity 0.000 claims description 6
- 108010002352 Interleukin-1 Proteins 0.000 claims description 5
- 238000009097 single-agent therapy Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 description 22
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010062878 Gastrooesophageal cancer Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000006974 gastroesophageal cancer Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662275127P | 2016-01-05 | 2016-01-05 | |
| US62/275,127 | 2016-01-05 | ||
| PCT/US2016/068945 WO2017120081A1 (en) | 2016-01-05 | 2016-12-28 | Methods of using interleukin-10 for treating diseases and disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019505493A JP2019505493A (ja) | 2019-02-28 |
| JP2019505493A5 true JP2019505493A5 (enExample) | 2020-02-13 |
Family
ID=59274328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531186A Withdrawn JP2019505493A (ja) | 2016-01-05 | 2016-12-28 | 疾患及び障害を治療するためにインターロイキン１０を使用する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20180369337A1 (enExample) |
| EP (1) | EP3400067A4 (enExample) |
| JP (1) | JP2019505493A (enExample) |
| KR (1) | KR20180100133A (enExample) |
| CN (1) | CN108430583A (enExample) |
| AU (1) | AU2016385474A1 (enExample) |
| CA (1) | CA3008284A1 (enExample) |
| MX (1) | MX2018007426A (enExample) |
| WO (1) | WO2017120081A1 (enExample) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2367891T3 (es) * | 2000-09-29 | 2011-11-10 | Schering Corporation | Interleucina-10 pegilada. |
| US20040009146A1 (en) * | 2002-02-26 | 2004-01-15 | Osvaldo Podhajcer | Anti-tumor vaccine and method |
| EP2066336B1 (en) * | 2006-09-28 | 2012-09-19 | Merck Sharp & Dohme Corp. | Use of pegylated il-10 to treat cancer |
| RU2679889C2 (ru) * | 2013-04-18 | 2019-02-14 | Армо Байосайенсиз, Инк. | Способы применения интерлейкина-10 для лечения заболеваний и расстройств |
-
2016
- 2016-12-28 US US16/061,583 patent/US20180369337A1/en not_active Abandoned
- 2016-12-28 EP EP16884214.4A patent/EP3400067A4/en not_active Withdrawn
- 2016-12-28 MX MX2018007426A patent/MX2018007426A/es unknown
- 2016-12-28 CA CA3008284A patent/CA3008284A1/en not_active Abandoned
- 2016-12-28 WO PCT/US2016/068945 patent/WO2017120081A1/en not_active Ceased
- 2016-12-28 AU AU2016385474A patent/AU2016385474A1/en not_active Abandoned
- 2016-12-28 JP JP2018531186A patent/JP2019505493A/ja not_active Withdrawn
- 2016-12-28 CN CN201680077588.8A patent/CN108430583A/zh active Pending
- 2016-12-28 KR KR1020187019681A patent/KR20180100133A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012532185A5 (enExample) | ||
| JP2019077723A (ja) | 抗ＣＴＬＡ−４抗体又は抗ＰＤ−１抗体との併用におけるＩＬ−２Ｒβ選択的作動薬 | |
| JP2021505661A5 (enExample) | ||
| JP2017533201A5 (enExample) | ||
| KR101848131B1 (ko) | 저용량 이리노테칸염산염 수화물을 함유하는 항종양제 | |
| JP2016514132A5 (enExample) | ||
| JP2018530525A5 (enExample) | ||
| US8710095B2 (en) | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity | |
| JP5881782B2 (ja) | 医薬組成物又は組合せ剤 | |
| CN109528731B (zh) | 具有协同作用治疗多发性骨髓瘤的药物组合物及其应用 | |
| JP2019505493A5 (enExample) | ||
| WO2020092650A1 (en) | Compositions and methods for modulating t cell exhaustion | |
| JP7412576B2 (ja) | 腎がんの相乗的治療におけるペグインターフェロンおよびプロトオンコジーン産物標的阻害剤の適用 | |
| EP2826482A1 (en) | Novel antitumor agent comprising combination of three agents | |
| JP6987271B2 (ja) | 新規キノカルコン化合物、及びがん又は炎症を治療するためのその用途 | |
| WO2006122431A1 (en) | Triazine compounds and compositions thereof for the treatment of cancers | |
| JP3064815B2 (ja) | ミエローマ系腫瘍抗癌剤 | |
| TW200740440A (en) | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | |
| CN112533605A (zh) | 用于治疗癌症的组合疗法 | |
| TWI727858B (zh) | 維奈托克(venetoclax)之水溶性高分子衍生物 | |
| EP1465617B1 (en) | Process for affecting neurologic progression | |
| NZ774138A (en) | Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent | |
| NZ774138B2 (en) | Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent | |
| RU2017144215A (ru) | Антибактериальные композиции | |
| HK1155062B (en) | Pharmaceutical composition and combined agent |